French drugmaker Sanofi and its British partner GlaxoSmithKline said a single booster dose of their recombinant adjuvanted Covid-19 vaccine candidate has delivered consistently strong immune responses.

"The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination," the companies said in a statement.

"To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022."

Read more from Reuters here.